Alfacell Corporation has said that the FDA has granted orphan-drug for its lead drug candidate, Onconase for treatment of malignant mesothelioma. Alfacell is evaluating Onconase in a confirmatory phase IIIb clinical trial in unresectable malignant mesothelioma.
Alfacell Corporation Granted U.S. Orphan Drug Designation For ONCONASE(R) For Treatment Of Malignant Mesothelioma
Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that the U.S. [click link for full article]